» Articles » PMID: 30651826

Saikosaponin D Inhibits Proliferation of Human Osteosarcoma Cells Via the P53 Signaling Pathway

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2019 Jan 18
PMID 30651826
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Saikosaponin D (SSd), the major monomeric terpenoid extracted from , a traditional Chinese medicinal herb, exerts various pharmacological properties, including antitumor, anti-inflammatory and antiviral. The present study aimed to investigate the role of SSd in human osteosarcoma (OS) cell growth. In the investigation MTS and EdU assays were applied and flow cytometric analyses of cell cycle and apoptosis were performed. Western blotting and reverse transcription-quantitative polymerase chain reaction analyses were used to explore the underlying mechanisms of SSd on cell cycle transition and p53 signaling. Here, it was demonstrated that SSd administration at 80 µmol/l significantly inhibited 143B and MG-63 proliferation. Furthermore, SSd significantly increased the percentage of 143B and MG-63 cells in G-G phase and the number of apoptosis cells compared with the control group. Data further demonstrated that SSd treatment upregulated mRNA and protein levels of tumor protein 53 (p53) and its downstream targets, including p21, p27, B-cell lymphoma-2-like protein 4 and cleaved caspase-3, and downregulated mRNA and protein levels of cyclinD1. The results suggested that SSd was a functional tumor suppressor and inhibited OS proliferation via activation of the p53 signaling pathway and may be used in the treatment of osteosarcoma in future.

Citing Articles

Research progress on the molecular mechanisms of Saikosaponin D in various diseases (Review).

Gu S, Zheng Y, Chen C, Liu J, Wang Y, Wang J Int J Mol Med. 2024; 55(3.

PMID: 39717942 PMC: 11722148. DOI: 10.3892/ijmm.2024.5478.


Saikosaponins Targeting Programmed Cell Death as Anticancer Agents: Mechanisms and Future Perspectives.

Xiao X, Gao C Drug Des Devel Ther. 2024; 18:3697-3714.

PMID: 39185081 PMC: 11345020. DOI: 10.2147/DDDT.S470455.


Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism.

Zhang Y, Wei J, Kong L, Song M, Zhang Y, Xiao X Aging (Albany NY). 2023; 15(11):5125-5143.

PMID: 37301545 PMC: 10292874. DOI: 10.18632/aging.204786.


Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy.

Yao P, Liu Y Molecules. 2023; 28(1).

PMID: 36615471 PMC: 9822439. DOI: 10.3390/molecules28010272.


Chemotherapeutic Potential of Saikosaponin D: Experimental Evidence.

Manoharan S, Deivendran B, Perumal E J Xenobiot. 2022; 12(4):378-405.

PMID: 36547471 PMC: 9782205. DOI: 10.3390/jox12040027.


References
1.
Kanthan R, Radhi J, Kanthan S . Gallbladder carcinomas: an immunoprognostic evaluation of P53, Bcl-2, CEA and alpha-fetoprotein. Can J Gastroenterol. 2000; 14(3):181-4. DOI: 10.1155/2000/865068. View

2.
Widhe B, Widhe T . Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am. 2000; 82(5):667-74. DOI: 10.2106/00004623-200005000-00007. View

3.
Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

4.
Hsu Y, Kuo P, Lin C . The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non-small cell lung cancer A549 cells. Life Sci. 2004; 75(10):1231-42. DOI: 10.1016/j.lfs.2004.03.008. View

5.
Hsu Y, Kuo P, Chiang L, Lin C . Involvement of p53, nuclear factor kappaB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer Lett. 2004; 213(2):213-21. DOI: 10.1016/j.canlet.2004.03.044. View